Ultragenyx Pharmaceutical, Inc. (RARE)
16.07
-0.20
(-1.23%)
USD |
NASDAQ |
Nov 13, 16:00
16.07
0.00 (0.00%)
After-Hours: 19:59
Ultragenyx Pharmaceutical Enterprise Value : 2.577B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 2.577B |
| November 11, 2026 | 2.621B |
| November 10, 2026 | 2.564B |
| November 09, 2026 | 2.591B |
| November 06, 2026 | 2.491B |
| November 05, 2026 | 2.506B |
| November 04, 2026 | 2.668B |
| November 03, 2026 | 2.614B |
| November 02, 2026 | 2.580B |
| October 30, 2026 | 2.560B |
| October 29, 2026 | 2.629B |
| October 28, 2026 | 2.672B |
| October 27, 2026 | 2.626B |
| October 26, 2026 | 2.558B |
| October 23, 2026 | 2.514B |
| October 22, 2026 | 2.544B |
| October 21, 2026 | 2.541B |
| October 20, 2026 | 2.551B |
| October 19, 2026 | 2.455B |
| October 16, 2026 | 2.401B |
| October 15, 2026 | 2.465B |
| October 14, 2026 | 2.437B |
| October 13, 2026 | 2.439B |
| October 12, 2026 | 2.478B |
| October 09, 2026 | 2.496B |
| Date | Value |
|---|---|
| October 08, 2026 | 2.477B |
| October 07, 2026 | 2.436B |
| October 06, 2026 | 2.392B |
| October 05, 2026 | 2.397B |
| October 02, 2026 | 2.470B |
| October 01, 2026 | 2.422B |
| September 30, 2026 | 2.451B |
| September 29, 2026 | 2.414B |
| September 28, 2026 | 2.325B |
| September 25, 2026 | 2.333B |
| September 24, 2026 | 2.360B |
| September 23, 2026 | 2.371B |
| September 22, 2026 | 2.443B |
| September 21, 2026 | 2.348B |
| September 18, 2026 | 2.334B |
| September 17, 2026 | 2.333B |
| September 16, 2026 | 2.174B |
| September 15, 2026 | 2.193B |
| September 14, 2026 | 2.246B |
| September 11, 2026 | 2.314B |
| September 10, 2026 | 2.324B |
| September 09, 2026 | 2.315B |
| September 08, 2026 | 2.371B |
| September 04, 2026 | 2.412B |
| September 03, 2026 | 2.368B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 4.834B |
| AbbVie, Inc. | 590.62B |
| Krystal Biotech, Inc. | 8.154B |
| BridgeBio Pharma, Inc. | 18.15B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -118.00M |
| Revenue (Quarterly) | 173.00M |
| Total Expenses (Quarterly) | 291.00M |
| EPS Diluted (Quarterly) | -1.156 |
| Gross Profit Margin (Quarterly) | 76.30% |
| Profit Margin (Quarterly) | -68.21% |
| Earnings Yield | -32.29% |
| Normalized Earnings Yield | -32.29 |